BNP Paribas Financial Markets Acquires 105,924 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

BNP Paribas Financial Markets grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 121.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,926 shares of the company's stock after purchasing an additional 105,924 shares during the quarter. BNP Paribas Financial Markets owned about 0.27% of Kiniksa Pharmaceuticals worth $4,821,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KNSA. FMR LLC boosted its position in Kiniksa Pharmaceuticals by 36,925.0% during the third quarter. FMR LLC now owns 696,810 shares of the company's stock worth $17,413,000 after purchasing an additional 694,928 shares during the period. Millennium Management LLC boosted its position in Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company's stock worth $11,612,000 after purchasing an additional 382,539 shares during the period. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company's stock worth $45,165,000 after purchasing an additional 223,094 shares during the period. Dimensional Fund Advisors LP boosted its position in Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock worth $12,398,000 after purchasing an additional 157,741 shares during the period. Finally, Harbor Capital Advisors Inc. bought a new position in Kiniksa Pharmaceuticals during the third quarter worth about $2,438,000. Institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total transaction of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at $2,923,205.25. This trade represents a 13.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 54.57% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Stock Performance

KNSA traded down $0.07 on Wednesday, reaching $21.10. The company had a trading volume of 70,218 shares, compared to its average volume of 401,105. The business has a 50 day simple moving average of $23.83 and a 200 day simple moving average of $23.00. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -151.20 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). The company had revenue of $112.21 million during the quarter, compared to analysts' expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's revenue for the quarter was up 67.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.20) earnings per share. As a group, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on KNSA shares. Evercore ISI increased their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a "buy" rating and a $40.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.